

Financial news for CLDN dated on 2016-03-09: Celladon Announces ISS, Glass Lewis Have Recommended Co. Holders Vote 'For' Proposed Deal

Financial news for CLDN dated on 2016-02-16: Celladon Extends Merger End Day With Eiger BioPharma to May 30, 2016

Financial news for CLDN dated on 2015-12-24: Boxer Capital Shows 5.9% Stake in Celladon

Financial news for CLDN dated on 2015-12-01: 8-K from Celladon Highlights Previously-Issued Press Release from Eiger BioPharma Announce Eiger's Orphan Drug Status for Ubenimex in PAH

Financial news for CLDN dated on 2015-11-30: CoLucid Pharmaceuticals Provides SAMURAI Enrollment Update

Financial news for CLDN dated on 2015-11-19: Street Watchdog Research Positive Report on Celladon

Financial news for CLDN dated on 2015-11-19: Morning Market Gainers

Financial news for CLDN dated on 2015-11-19: Benzinga's Top #PreMarket Gainers

Financial news for CLDN dated on 2015-11-19: UPDATE: Celladon +170% Premarket @\$3.00 Following Announcement of Merger With Eiger BioPharmaceuticals

Financial news for CLDN dated on 2015-11-19: Celladon +58% Premarket @\$1.76 Following Announcement of Merger With Eiger BioPharmaceuticals

Financial news for CLDN dated on 2015-11-19: Eiger BioPharmaceuticals, Celladon Announce Merger Agreement; Investor Syndicate to Invest \$39.5M In Combined Co

Financial news for CLDN dated on 2015-08-11: Celladon Says Company Evaluating Strategic Alternatives in Light of Negative Cupid2 Data

Financial news for CLDN dated on 2015-06-26: Friday's Mid-Day Movers: Micron, Winnebago, Cleveland BioLabs And More

Financial news for CLDN dated on 2015-06-26: Stocks Hitting 52-Week Lows

Financial news for CLDN dated on 2015-06-26: Morning Market Losers

Financial news for CLDN dated on 2015-06-26: Cealladon Shares Fall 40% Premarket Following Announcement it's Suspending Development of Mydicar

Financial news for CLDN dated on 2015-06-26: Cealladon Is in Process of Merging or Finding Acquirer, Suspending Development of Mydicar

Financial news for CLDN dated on 2015-06-01: Morning Market Gainers

Financial news for CLDN dated on 2015-06-01: Celladon Offers Strategic Direction Following CUPID2 Data Review: Will Seek Acquisition or Partnership

Financial news for CLDN dated on 2015-05-20: Celladon Shares Move Higher; May be Attributed to Updated EMA Guidelines

Financial news for CLDN dated on 2015-05-15: Stocks Hitting 52-Week Lows

Financial news for CLDN dated on 2015-05-15: Morning Market Losers

Financial news for CLDN dated on 2015-05-15: Benzinga's Top #PreMarket Losers

Financial news for CLDN dated on 2015-05-14: Celladon Announces Evaluating Strategic Options

Financial news for CLDN dated on 2015-05-14: Celladon Reports Q1 Loss of \$16.7M vs \$7.2M Loss in Same Qtr. Last Year

Financial news for CLDN dated on 2015-04-30: 8-K from Celladon Shows Co. to Terminate Novasep Pact, Says Will Cut Headcount by 50%

Financial news for CLDN dated on 2015-04-28: H.C. Wainwright Downgrades Celladon to Neutral

Financial news for CLDN dated on 2015-04-28: Morning Market Gainers

Financial news for CLDN dated on 2015-04-28: Benzinga's Top #PreMarket Gainers

Financial news for CLDN dated on 2015-04-27: Gene Therapy Stocks Take Beating On Bad

News For Celladon

Financial news for CLDN dated on 2015-04-27: Stocks Hitting 52-Week Lows

Financial news for CLDN dated on 2015-04-27: Morning Market Losers

Financial news for CLDN dated on 2015-04-27: Wedbush Just Downgraded Celladon To Neutral And Slashed Its PT By \$26

Financial news for CLDN dated on 2015-04-27: Benzinga's Top #PreMarket Losers

Financial news for CLDN dated on 2015-04-27: Wedbush Downgrades Celladon to Neutral, Lowers PT to \$3.00

Financial news for CLDN dated on 2015-04-27: Adam Feuerstein @adamfeuerstein Tweet: From last night --> Gene Therapy Stocks on Watch Following Failure of \$CLDN Heart Failure Trial thestreet.com/story/13126476... \$BLUE \$QURE \$ONCE

Financial news for CLDN dated on 2015-04-27: Roth Capital Downgrades Celladon to Neutral

Financial news for CLDN dated on 2015-04-27: Celladon Shares Fall 75% Premarket on Failed CUPID2 Trial of MYDICAR in Advanced Heart Failure

Financial news for CLDN dated on 2015-04-26: Celladon CUPID2 Trial of MYDICAR in Advanced Heart Failure Fails to Meet Primary, Secondary Endpoints

Financial news for CLDN dated on 2015-04-22: BMO Capital Initiates Coverage on Celladon at Market Perform, Announces \$15.00 PT

Financial news for CLDN dated on 2015-04-07: H.C. Wainwright Initiates Coverage On Celladon, Cites Impressive Trial Results For Heart Failure Therapy

Financial news for CLDN dated on 2015-04-07: HC Wainwright Initiates Coverage on Celladon at Buy, Announces \$31.00 PT

Financial news for CLDN dated on 2015-03-31: S-3 from Celladon Shows Registration for 7M Share Shelf Offering

Financial news for CLDN dated on 2015-03-31: Morning Market Losers

Financial news for CLDN dated on 2015-03-31: Benzinga's Top #PreMarket Losers

Financial news for CLDN dated on 2015-03-30: Celladon Reports Q4 Consolidated Loss ~\$11.34M vs Loss of ~\$6.18M in Same Qtr. Last Year

Financial news for CLDN dated on 2015-03-24: Kofax, Lexmark And Christopher & Banks Lead Tuesday's After-Hours Movers

Financial news for CLDN dated on 2015-03-24: Novasep, Celladon Execute MYDICAR API Supply Agreement

Financial news for CLDN dated on 2015-03-06: Benzinga's Volume Movers

Financial news for CLDN dated on 2015-03-06: Stocks Hitting 52-Week Highs

Financial news for CLDN dated on 2015-03-05: Benzinga's Volume Movers

Financial news for CLDN dated on 2015-03-05: Morning Market Gainers

Financial news for CLDN dated on 2015-03-05: Roth Capital Initiates Celladon At Buy

Financial news for CLDN dated on 2015-03-05: Benzinga's Top Initiations

Financial news for CLDN dated on 2015-03-05: Benzinga's Top #PreMarket Gainers

Financial news for CLDN dated on 2015-03-05: Roth Capital Initiates Coverage on Celladon at Buy

Financial news for CLDN dated on 2015-01-05: Celladon Reports Conducting of Initial Scale Up of Manufacturing Process for MYDICAR to Commercial Scale

Financial news for CLDN dated on 2014-11-03: Celladon Reports Lonza to Begin Design of New Commercial Viral Therapeutics Facility In Portsmouth, NH

Financial news for CLDN dated on 2014-10-27: Celladon Corporation Announces Publication of Data From Its Stem Cell Factor Gene Therapy Program in Circulation Heart Failure

Financial news for CLDN dated on 2014-08-12: Celladon Prices 4M Shares at \$9.50/Share

Financial news for CLDN dated on 2014-08-07: Celladon Reports Q2 Loss of \$7M

Financial news for CLDN dated on 2014-08-07: Celladon to Offer 4M Shares

Financial news for CLDN dated on 2014-07-30: S-1 from Celladon Shows Filing for \$63.3M in Shares

Financial news for CLDN dated on 2014-07-21: Celladon Corporation Announces In-License Of Stem Cell Factor Development Program

Financial news for CLDN dated on 2014-07-07: Celladon Announces Plans To Initiate 100 Patients Phase 2a Trial For Mydicar In ESRD Patients and Phase 1/2 Study For Heart Failure Patients

Financial news for CLDN dated on 2014-06-04: Mid-Day Market Movers For Wednesday, June 4, 2014

Financial news for CLDN dated on 2014-06-02: Celladon Announces Paul Cleveland President and CFO

Financial news for CLDN dated on 2014-04-10: Morning Market Movers

Financial news for CLDN dated on 2014-04-10: Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR

Financial news for CLDN dated on 2014-04-01: Celladon Added to Russel 200, Russel 3000

Financial news for CLDN dated on 2014-03-04: Celladon Completes Enrollment of CUPID 2 Trial for Advanced Heart Failure

Financial news for CLDN dated on 2014-02-27: Celladon Announces Exercise in Full, Closing of Underwriters' Overallotment Option

Financial news for CLDN dated on 2014-02-24: Morning Market Movers

Financial news for CLDN dated on 2014-02-24: UPDATE: Stifel Initiates Coverage on Celladon as Novel Gene Therapy Could Revolutionize Heart Failure Treatment